ArticleBBA advances2025
Identification of aberrant α-2,3 sialylation of cartilage associated with osteonecrosis of the femoral head based on integrated multi-omics analyses.
Article in BBA advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Osteonecrosis of the femoral head (ONFH) is one of the most common and devastating articular cartilage diseases worldwide. The role of glycosylation in cartilage degeneration of ONFH is not yet fully understood. Patients and methods: The expression of glycogens in cartilage from ONFH patients was determined using our own whole-genome expression dataset. Moreover, the altered glycosylation associated with ONFH cartilage and methylprednisolone (MPS)-induced cell models was investigated by lectin microarrays. The synthesis of α-2,3 sialylation was repressed by silencing ST3GAL2, and the effect of α-2,3-sialylation on ONFH-associated molecular events was assessed. Results: Our findings revealed that the expression of 18 glycogens (including ST3GAL2) were significantly changed in ONFH cartilage compared with those in fracture control cartilage. Moreover, the level of α-2,3 sialylation, which is catalyzed by ST3GAL2, was significantly increased in ONFH cartilage and cell models compared to their corresponding controls. Silencing the expression of ST3GAL2 not only reduced the level of α-2,3 sialylation but also suppressed the expression of proinflammatory cytokines, reduced apoptosis-related proteins, and inactivated the NF-κB signaling pathway. Conclusion: Our study highlighted the important role of α-2,3 sialylation in the development of ONFH, providing valuable insights into the molecular mechanisms underlying the pathogenesis of ONFH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.